<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158597</url>
  </required_header>
  <id_info>
    <org_study_id>5172011</org_study_id>
    <nct_id>NCT03158597</nct_id>
  </id_info>
  <brief_title>Transcriptome Study of Acute Myocardial Infarction</brief_title>
  <official_title>Screening Pathogenic Genes Associated With Acute Myocardial Infarction and Studying Its Relevant Molecular Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare whole-blood microarray gene-expression profiling between patients&#xD;
      with acute myocardial infarction and normal participants without cardiovascular diseases.&#xD;
      Firstly, screening differentially genes of mRNA to perform gene ontology and pathway&#xD;
      analysis. Secondly, predicting target genes regulated by microRNA and constructing&#xD;
      coexpression network with mRNA. Thirdly, biological function experiment of microRNA. Finally,&#xD;
      revealing pathogenic mechanisms associated with acute myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of screening differentially expressed genes associated with acute myocardial infarction as measured by microarray</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>AMI</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        AMI patients will be selected from Emergency Department of Beijing An Zhen Hospital or&#xD;
        Beijing Tong Ren Hospital.&#xD;
&#xD;
        Normal control participants will be recruited from Health Examination Center of Beijing An&#xD;
        Zhen Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AMI patients:&#xD;
&#xD;
               1. 20-50 years of age&#xD;
&#xD;
               2. Symptoms of ischaemia&#xD;
&#xD;
               3. New significant ST-segment-T wave changes in ECG and definitive diagnosis of&#xD;
                  non-ST elevation MI or ST elevation MI&#xD;
&#xD;
               4. Cardiac troponin with at least one value above the 99th percentile upper&#xD;
                  reference limit&#xD;
&#xD;
          -  Normal control participants:&#xD;
&#xD;
               1. 20-50 years of age&#xD;
&#xD;
               2. Normal ECG&#xD;
&#xD;
               3. BMI &lt;24kg/m2&#xD;
&#xD;
               4. systolic blood pressure &lt;140mmHg&#xD;
&#xD;
               5. diastolic blood pressure &lt;90mmHg&#xD;
&#xD;
               6. Total cholesterol &lt;200mg/dl (5.18mmol/L)&#xD;
&#xD;
               7. Triglyceride &lt;150mg/dl (1.70mmol/L)&#xD;
&#xD;
               8. High density lipoprotein cholesterol &gt;=40mg/dl (1.04mmol/L)&#xD;
&#xD;
               9. Low density lipoprotein cholesterol &lt;130mg/dl (3.37mmol/L)&#xD;
&#xD;
              10. Fasting blood glucose &lt;100mg/dl (5.6mmol/L)&#xD;
&#xD;
              11. Not taking antihypertensive or hypolipidemic or hypoglycemic drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new&#xD;
             ischaemic ECG changes, but death occurred before cardiac biomarkers were obtained, or&#xD;
             before cardiac biomarker values would be increased&#xD;
&#xD;
          2. Prior myocardial infarction&#xD;
&#xD;
          3. Percutaneous coronary intervention related MI&#xD;
&#xD;
          4. Stent thrombosis associated with MI&#xD;
&#xD;
          5. Coronary artery bypass grafting related MI&#xD;
&#xD;
          6. Recurrent MI or reinfarction&#xD;
&#xD;
          7. Myocardial injury with necrosis caused by transcatheter aortic valve implantation or&#xD;
             mitral clip or ablation of arrhythmias&#xD;
&#xD;
          8. Myocardial injury or infarction associated with heart failure&#xD;
&#xD;
          9. Myocardial infarction in the intensive care unit&#xD;
&#xD;
         10. Other diseases: previous history of ASCVD, cancer, rheumatoid arthritis, liver or&#xD;
             kidney disease, myeloproliferative disorders, chronic inflammation, peripheral&#xD;
             vascular disease&#xD;
&#xD;
         11. Not available informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Chaoyang</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Li</last_name>
      <phone>861064456736</phone>
      <email>torrancely@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Institute of Heart, Lung and Blood Vessel Diseases</investigator_affiliation>
    <investigator_full_name>Yan Li</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 21, 2020</submitted>
    <returned>January 29, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

